Ramalingam SS - Search Results

1

Retinoic acid enhances TRAIL-induced apoptosis in cancer cells by upregulating TRAIL receptor 1 expression.

Dhandapani L, Yue P, Ramalingam SS, Khuri FR, Sun SY. Dhandapani L, et al. Among authors: ramalingam ss. Cancer Res. 2011 Aug 1;71(15):5245-54. doi: 10.1158/0008-5472.CAN-10-4180. Epub 2011 Jun 17. Cancer Res. 2011. PMID: 21685476 Free PMC article.

2

Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy.

Wang X, Hawk N, Yue P, Kauh J, Ramalingam SS, Fu H, Khuri FR, Sun SY. Wang X, et al. Among authors: ramalingam ss. Cancer Biol Ther. 2008 Dec;7(12):1952-8. doi: 10.4161/cbt.7.12.6944. Epub 2008 Dec 8. Cancer Biol Ther. 2008. PMID: 18981735 Free PMC article.

3

The role of the taxanes in the treatment of older patients with advanced stage non-small cell lung cancer.

Ramalingam SS, Khuri FR. Ramalingam SS, et al. Oncologist. 2009 Apr;14(4):412-24. doi: 10.1634/theoncologist.2008-0190. Epub 2009 Apr 2. Oncologist. 2009. PMID: 19342473 Free article. Review.

4

Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues.

Fan S, Ramalingam SS, Kauh J, Xu Z, Khuri FR, Sun SY. Fan S, et al. Among authors: ramalingam ss. Cancer Biol Ther. 2009 Aug;8(15):1463-9. doi: 10.4161/cbt.8.15.8960. Epub 2009 Aug 8. Cancer Biol Ther. 2009. PMID: 19483468 Free PMC article.

5

The role of cetuximab in the management of non-small-cell lung cancer.

Owonikoko TK, Sun SY, Ramalingam SS. Owonikoko TK, et al. Among authors: ramalingam ss. Clin Lung Cancer. 2009 Jul;10(4):230-8. doi: 10.3816/CLC.2009.n.031. Clin Lung Cancer. 2009. PMID: 19632939 Review.

6

Preoperative therapy for early-stage NSCLC: opportunities and challenges.

Owonikoko TK, Khuri FR, Ramalingam SS. Owonikoko TK, et al. Among authors: ramalingam ss. Oncology (Williston Park). 2009 Sep;23(10):886, 889, 892. Oncology (Williston Park). 2009. PMID: 19839430 Free article. No abstract available.

7

PI3 kinase, mTOR, and AKT pathways.

Ramalingam SS, Khuri FR. Ramalingam SS, et al. J Thorac Oncol. 2009 Nov;4(11 Suppl 3):S1059-60. doi: 10.1097/01.JTO.0000361749.02166.1a. J Thorac Oncol. 2009. PMID: 19861916 Free article. No abstract available.

8

Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer.

Ramalingam SS, Foster J, Gooding W, Evans T, Sulecki M, Belani CP. Ramalingam SS, et al. Cancer. 2010 Mar 1;116(5):1344-9. doi: 10.1002/cncr.24753. Cancer. 2010. PMID: 20082454 Free article. Clinical Trial.

9

Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.

Ramalingam SS, Harvey RD, Saba N, Owonikoko TK, Kauh J, Shin DM, Sun SY, Strychor S, Tighiouart M, Egorin MJ, Fu H, Khuri FR. Ramalingam SS, et al. Cancer. 2010 Aug 15;116(16):3903-9. doi: 10.1002/cncr.25264. Cancer. 2010. PMID: 20564143 Free PMC article. Clinical Trial.

10

Lung cancer in the elderly: what's age got to do with it?

Owonikoko TK, Ramalingam SS, Khuri FR. Owonikoko TK, et al. Among authors: ramalingam ss. Oncology (Williston Park). 2010 Nov 15;24(12):1120, 1122, 1129. Oncology (Williston Park). 2010. PMID: 21141693 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

399 results

Search Page

Filters